AGP Limited is proud to be recognized as one of the ‘Top Exporter’ at the 7th Pharma Export Summit & Awards 2024.

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > Cinklare

Product List

Cinklare

Generic:

Cefixime

 

Therapeutic Class:

Cephalosporin Oral

 

Composition:

 

Cinklare cap 400 mg:

Each Cinklare cap contains cefixime trihydrate USP equivalent to cefixime 400 mg.

Cinklare dry susp 100 mg/5 ml:

Each 5 ml of reconstituted susp contains cefixime trihydrate USP equivalent to cefixime 100 mg.

Cinklare dry susp 200 mg/5 ml:

Each 5 ml of reconstituted susp contains
cefixime trihydrate USP equivalent to cefixime 200 mg.

 

Description:

Cinklare (Cefixime) is an antibacterial, belonging to the drug class of 3rd generation cephalosporin.

 

Indications:

Uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including penicillinase (beta-lactamase-positive) and nonpenicillinase (beta-lactamase-negative) producing strains..

Cinklare is indicated in the treatment of
adults and pediatric patients six months of age or older with the following
infections when caused by susceptible isolates of the designated bacteria:

Upper
Respiratory Tract:

Pharyngitis and
tonsillitis caused by S. pyogenes.

Middle
Ear:

Otitis media caused
by S. pneumoniae, H. influenzae (beta-lactamase positive and negative
strains), M. catarrhalis (former B. catarrhalis) (beta-lactamase
positive and negative strains) and S. pyogenes.

Paranasal
sinuses:

Sinusitis caused by S.
pneumoniae, H. influenzae
(beta-lactamase positive and negative strains),
and M. catarrhalis (former B. catarrhalis) (beta-lactamase
positive and negative strains).

Lower Respiratory Tract:

Acute bronchitis
caused by S. pneumoniae, M. catarrhalis (former B. catarrhalis)
(beta-lactamase positive and negative strains) and H. influenzae (beta-lactamase
positive and negative strains).

Urinary
Tract:

Acute uncomplicated
cystitis and urethritis caused by E. coli, P. mirabilis, and Klebsiella
species.

Uncomplicated Gonorrhea:

Uncomplicated
gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae,
including penicillinase (beta-lactamase-positive) and nonpenicillinase
(beta-lactamase-negative) producing strains. 

 

Dosage:

The
recommended dose of cefixime is 8 mg/kg/day once daily. When necessary, a dose
of 4 mg/kg given twice daily may be considered except for urinary tract
infections where once daily dosing must be used.

Adults:
The recommended dose of
cefixime is 400 mg once daily. When necessary, a dose of 200 mg (one-half of a
400 mg tablet) given twice daily may be considered except for urinary tract
infections where once daily dosing must be used.

For treatment of uncomplicated gonococcal
infections, a single oral dose of 400 mg is recommended.

Children (≥ 6 months):

The recommended dose of cefixime is 8 mg/kg/day once daily. When necessary, a dose of 4 mg/kg given twice daily may be considered except for urinary tract infections where once daily dosing must be used. 

 

Children weighing more than 50 kg or older
than 12 years should be treated with the recommended adult dose. Safety and
effectiveness in infants aged less than six months have not been established. 

Presentation:

  • Cinklare Dry Susp 100 mg/5 ml: Bottle of 30 ml susp
  • Cinklare Dry Susp 200 mg/5 ml: Bottle of 30 ml susp
  • Cinklare Caps 400 mg: Pack of 5 caps